PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742789
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742789
Global Peripherally Inserted Central Catheters Market to Reach US$1.0 Billion by 2030
The global market for Peripherally Inserted Central Catheters estimated at US$868.3 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Conventional PICC, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$638.9 Million by the end of the analysis period. Growth in the Power Injected PICC segment is estimated at 2.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$236.6 Million While China is Forecast to Grow at 5.2% CAGR
The Peripherally Inserted Central Catheters market in the U.S. is estimated at US$236.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$198.0 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
Global Peripherally Inserted Central Catheters Market - Key Trends & Drivers Summarized
Why Are Peripherally Inserted Central Catheters Gaining Preference Over Conventional Central Lines?
Peripherally Inserted Central Catheters (PICCs) are witnessing increased clinical adoption due to their minimally invasive nature and versatility in delivering long-term intravenous therapies. Unlike traditional central venous catheters that require insertion in the subclavian or jugular vein, PICCs are inserted into peripheral veins (typically in the arm) and advanced to the superior vena cava, offering a safer and more accessible route for infusion therapy. This advantage is particularly crucial for patients undergoing chemotherapy, parenteral nutrition, or extended antibiotic regimens, where long-term vascular access is essential.
One of the key shifts favoring PICCs is their ability to be inserted at the bedside by specially trained nursing staff, eliminating the need for surgical suite occupancy and reducing procedural delays. Additionally, ultrasound and ECG-guided placement technologies have significantly enhanced insertion accuracy and safety, minimizing complications such as pneumothorax, arterial puncture, and catheter malposition. These benefits, combined with lower insertion costs and improved patient comfort, are propelling PICCs as the preferred vascular access method in both inpatient and outpatient care settings.
How Are Infection Control Standards, Antimicrobial Technologies, and Patient Stratification Redefining PICC Use?
The global focus on infection prevention in clinical care is placing significant emphasis on catheter-associated bloodstream infection (CABSI) reduction. PICC manufacturers are responding with advanced catheter materials embedded with antimicrobial coatings such as chlorhexidine, silver ions, or rifampin-minocycline combinations. These coatings not only reduce bacterial colonization but also extend dwell time, making PICCs more reliable for long-term use in immunocompromised and critically ill patients.
Stratified care pathways are also influencing PICC usage patterns. In oncology, PICCs offer a central line alternative that reduces the risk of thrombosis and facilitates outpatient chemotherapy regimens. In home infusion therapy, patients with chronic infections or gastrointestinal disorders are now managed via PICCs supported by mobile care teams, improving continuity and reducing hospital readmission rates. Clinical algorithms based on dwell time, infusion type, and venous condition are increasingly guiding vascular access decisions, leading to more targeted and efficient use of PICCs.
Why Are Technological Advancements and Integrated Care Models Expanding Market Adoption?
Innovations in catheter design and placement are enhancing clinical outcomes and procedural workflow. Power-injectable PICCs capable of withstanding high flow rates are gaining popularity in diagnostic imaging and contrast-based interventions. Additionally, the introduction of pressure-sensitive valves, biofilm-resistant polymers, and securement devices is minimizing the risk of catheter dislodgment, occlusion, and infection-leading to fewer complications and improved patient outcomes.
Integrated care models are also playing a key role in expanding the PICC market. Hospitals are establishing dedicated vascular access teams that streamline PICC placement, maintenance, and removal protocols, thus standardizing best practices and reducing complication rates. In ambulatory care and long-term acute care settings, PICCs are being embedded into chronic disease management frameworks, supported by telehealth monitoring and home care nursing-extending the reach of central venous access beyond the hospital walls.
What’s Driving the Growth of the Peripherally Inserted Central Catheters Market Worldwide?
The growth in the peripherally inserted central catheters market is driven by several factors including the increasing need for long-term intravenous therapy, rising healthcare decentralization, and advancements in infection control technologies. A primary growth driver is the growing population of cancer patients, individuals with chronic infections, and elderly patients who require safe, repeatable, and extended vascular access solutions.
Additionally, the global trend toward reducing hospital stays and shifting care to outpatient or home-based models is accelerating PICC placement across a broader patient base. Health systems focused on cost containment, patient-centered care, and infection prevention are prioritizing PICCs for their clinical and economic advantages. With the convergence of portable imaging, real-time placement guidance, and catheter material innovation, the PICC market is set to expand as a cornerstone of modern intravenous access strategies in both developed and emerging economies.
SCOPE OF STUDY:
The report analyzes the Peripherally Inserted Central Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Conventional PICC, Power Injected PICC, Neonatal PICC); Lumen Type (Single Lumen, Double Lumen, Multiple Lumen); Application (Chemotherapy, Long-Term Iv Infusion, Parenteral Nutrition, Blood Transfusion, Difficult Intravenous Access, Other Applications); End-Use (Hospitals, Cancer Research Institutes, Long Term Care Centers, Independent Infusion Centers, Ambulatory Surgical Center, Home Care Settings, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.